Summary
Celgene had some bad news, driving the stock to bargain prices in 2018.
Ozanimod and Fedratinib applications to the FDA will be good signs.
Multiple sales generators are already easing dependence of Revlimid sales.
Celgene (CELG) is a pharmaceutical discovery juggernaut that has positioned itself to be among the higher profit generators in its sector in the coming decade. Yet the stock is cheap today by any rational assessment. I have been accumulating more of it this year. I first bought it in 2007 and accumulated it through the 2008 market downturn.
I will show that the current negative stories about Celgene are overblown. The positive stories about the coming decade are the real story that decisions about this stock should be based on.
This article is an attempt to look at the overall picture objectively. Celgene is a very complex stock to analyze because it has many moving parts, including drugs that are already commercial, are nearing commercial release, are in the clinical stage, and are preclinical. Future profits depend on this entire picture.
